Product Dossier
CADIVAST
Product Dossier for CADIVAST (amlodipine, atorvastatin, Alphapharm). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: Alphapharm
- Active ingredient: amlodipine, atorvastatin
- Therapeutic area: Cardiology
- Related brand: NORVASC
- Related brand: ATOZET
- Related brand: LIPITOR
- Same area: OPSUMIT
- Same area: TARKA
What it is
CADIVAST is a fixed-dose combination tablet containing amlodipine (as besilate) and atorvastatin (as calcium). It is available in eight strengths: 5/10 mg, 5/20 mg, 5/40 mg, 5/80 mg, 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg.
Approved indications
The provided source documents do not contain information about the approved therapeutic indications for CADIVAST.
Dosing overview
The provided source documents do not contain dosing information for CADIVAST.
Key safety warnings
The provided source documents do not contain safety warning information specific to CADIVAST.
Contraindications
The provided source documents do not contain contraindication information for CADIVAST.
PBS listing
The provided source documents do not contain Pharmaceutical Benefits Scheme listing information for CADIVAST.
Regulatory history
CADIVAST was registered on the Australian Register of Therapeutic Goods (ARTG) on 9 January 2014 under licence category RE (restricted export).